Cancer combo trial pulled before it even started
NCT ID NCT05982522
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to test a new oral drug called IN10018 combined with chemotherapy (nab-paclitaxel) and an immunotherapy (tislelizumab) in people with advanced solid tumors, specifically non-small cell lung cancer, that had stopped responding to prior treatments. The goal was to see if the combination could shrink tumors and to find the safest dose. However, the trial was withdrawn before enrolling any participants, so no data were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IN10018 (a drug taken by mouth) combined with nab-paclitaxel (chemotherapy) and tislelizumab (immunotherapy)
What this could lead to
If it works, this combination could offer a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
The trial was withdrawn before enrolling any participants, so no results are available. It is unclear if the combination is safe or effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.